10/28/2026
Eloralintide is one of the most talked-about weight loss drugs in trials right now. But it isn’t a GLP-1. It copies amylin, a “fullness” hormone you’ve probably never heard of. đź§
Your pancreas releases amylin with insulin after you eat. It helps you feel full sooner, slows how fast food leaves your stomach, and keeps blood sugar from spiking after meals.
Eloralintide belongs to a drug class called amylin receptor agonists:
✔️ In a 48-week Phase 2 trial, eloralintide led to 9.5% to 20.1% average weight loss, depending on the dose
✔️ It’s now in Phase 3 and is not FDA-approved
✔️ The only approved amylin drug, pramlintide (Symlin), is for diabetes, not weight loss
How eloralintide and other amylin drugs work, in plain English 👉 https://pharmagiant.com/amylin-receptor-agonist/
Had you heard of eloralintide before today? Yes or no 👇